Quirky Novartis Bet Pushes Biopharma M&A Beyond $100 Billion
Novartis is buying Avidity Biosciences in a $12 billion deal
Signage for Novartis AG on a building in the company's headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023.
Photographer: Stefan Wermuth/BloombergThis article is for subscribers only.
Hi, it’s Michelle F. Davis in New York, looking at a unique piece of M&A in the biotech sector. Also today, a Merger Monday brings some big deals in banking and utilities, and Nelson Peltz wants all of Janus Henderson.
Today’s top stories